AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, announced today that a moderated poster presentation will be made at the Emerging Technology session of the American Society of Regional Anesthesia and Pain Medicine (ASRA) 14th Annual Pain Medicine Meeting to be held November 19th to November 21st at the Fontainebleau Miami Beach in Miami, Florida. The annual ASRA meeting is the foremost scientific and educational event on invasive and non-invasive targeted therapies in pain medicine and brings together nearly 1,000 national and international thought leaders. Pamela Palmer, M.D. Ph.D., AcelRx Co-founder and Chief Medical Officer, will present safety and efficacy data from a Phase 3 trial, SAP301, evaluating the sufentanil sublingual 30 mcg tablet, or ARX-04, for the treatment of acute pain following ambulatory surgery.
Details on the presentation times are as follows:
Thursday, November 19, 2015 – Emerging Technology Moderated Poster Session, MP-02, Presentation time 10:45-12:45pm (local time), Splash 13
|Authors:||Harold Minkowitz, MD, Shankar Lakshman, MD, Timothy Melson, MD, David Leiman, MD, Karen DiDonato, MSN, RN and Pamela Palmer, MD, PhD|
|Title:||Safety and Efficacy Subgroup Analysis by Age of Sufentanil Sublingual 30 mcg Tablets for the Treatment of Acute Pain following Outpatient Abdominal Surgery (Original Source)|
Shares of Acelrx Pharmaceuticals closed yesterday at $5.25. ACRX has a 1-year high of $9.32 and a 1-year low of $2.92. The stock’s 50-day moving average is $3.96 and its 200-day moving average is $3.96.
On the ratings front, Acelrx has been the subject of a number of recent research reports. In a report issued on October 30, Jefferies Co. analyst Hugo Ong upgraded ACRX to Buy, with a price target of $7, which implies an upside of 33.3% from current levels. Separately, on October 8, Cowen’s Boris Peaker reiterated a Hold rating on the stock .
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Hugo Ong and Boris Peaker have a total average return of 17.7% and 22.9% respectively. Ong has a success rate of 100.0% and is ranked #2306 out of 3855 analysts, while Peaker has a success rate of 46.2% and is ranked #97.
Overall, one research analyst has assigned a Hold rating and 3 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $8.67 which is 65.1% above where the stock closed yesterday.
AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of therapies for the treatment of acute pain.